Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Therapy Response
100%
Papillary Thyroid Carcinoma
100%
Differentiated Thyroid Carcinoma
100%
Translational Regulation
100%
Radioactive Iodine Therapy
100%
Glycosylphosphatidylinositol Transamidase
50%
Tumor
25%
MEK Inhibitor (MEKi)
25%
Papillary Carcinoma
25%
Carcinoma Cell Lines
25%
Radioactive Iodine
25%
Transamidase Complex
25%
Radioactive Iodine Resistance
25%
Expression Level
12%
Cell Membrane
12%
Expression Pattern
12%
Confidence Interval
12%
Glycosylation
12%
Logistic Regression Model
12%
Low Expression
12%
Novel Mechanism
12%
Hazard Ratio
12%
Statistical Test
12%
Uptake Assay
12%
Multivariable Logistic Regression
12%
U0126
12%
Radioactive Iodine Uptake
12%
Normal Thyroid
12%
Expression Profiling
12%
Iodine Uptake
12%
Radioiodine Uptake
12%
Thyroid Tissue
12%
Biochemical Response
12%
Human Sodium Iodide Symporter (hNIS)
12%
Iodine Avidity
12%
Thyroid Carcinoma Cells
12%
Medicine and Dentistry
Treatment Response
100%
Papillary Thyroid Cancer
100%
Radioactive Iodine
100%
Protein Processing
100%
Differentiated Thyroid Cancer
88%
Glycosylphosphatidylinositol
44%
In Vitro
22%
Tumor
22%
Biopsy Technique
11%
Downregulation
11%
Iodine 125
11%
Logistic Regression Analysis
11%
Cell Membrane
11%
Hazard Ratio
11%
Papillary Carcinoma
11%
Uptake Assay
11%
Glycosylation
11%
Sodium Iodide Symporter
11%
MEK Inhibitor
11%
U0126
11%
Papillary Carcinoma Cell Line
11%
Thyroid Carcinoma Cell Line
11%
Neuroscience
Thyroid
100%
Posttranslational Modification
100%
Glycosylphosphatidylinositol
40%
Cell Line
20%
In Vivo
20%
In Vitro
20%
Cell Membrane
10%
Iodine-125
10%
Glycosylation
10%
MEK Inhibitor
10%
U0126
10%
Sodium Iodide Symporter
10%
Biochemistry, Genetics and Molecular Biology
Posttranslational Modification
100%
Tincture of Iodine
100%
Glycosylphosphatidylinositol
44%
Cell Membrane
11%
Downregulation
11%
Glycosylation
11%
Iodine-125
11%
Statistical Test
11%
Avidity
11%
MEK Inhibitor
11%
U0126
11%
Sodium-Iodide Symporter
11%